Dorixina B1 B6 B12: Comprehensive Pain Relief and Nerve Support

What is Dorixina B1 B6 B12?

Dorixina B1 B6 B12 combines the powerful analgesic properties of Lysine Clonixinate with the neuroprotective benefits of Vitamin B Complex (B1, B6, B12). This dual-action formula is designed to relieve pain while supporting nerve health, making it a trusted solution for musculoskeletal and neuropathic conditions.

Key Benefits

1. Effective Pain Relief:

   • Lysine Clonixinate reduces pain and inflammation by selectively inhibiting prostaglandin synthesis (COX-2).

2. Nerve Health Support:

   • Vitamin B1 (Thiamine): Boosts energy metabolism and supports nerve function.
   • Vitamin B6 (Pyridoxine): Enhances neurotransmitter function and brain health.
   • Vitamin B12 (Cyanocobalamin): Aids in myelin synthesis, red blood cell formation, and DNA repair.

3. Dual Action Formula:

   • Combines pain relief and nerve regeneration for a holistic approach to patient care.

Indications

Dorixina B1 B6 B12 is indicated for:

• Acute musculoskeletal inflammatory processes with neuritic components.
• Conditions where mono-substance treatments have been insufficient.

How to Use Dorixina B1 B6 B12

• Dosage: 1 tablet, 3-4 times daily, as prescribed by your healthcare provider.
• Maximum Daily Dose: 6 tablets.
• Administration: Swallow tablets whole with a full glass of water.

Why Choose Dorixina B1 B6 B12?

• Innovative Combination: Relief for pain and support for nerve health in one solution.
• Trusted Quality: Manufactured by Roemmers, a leader in pharmaceutical innovation.
• Targeted Relief: Ideal for patients with pain and nerve conditions requiring comprehensive care

Precautions and Warnings

• Do Not Use If:

  • You have hypersensitivity to any of the ingredients.
  • You have active peptic ulcers or gastroduodenal hemorrhage.
  • You are pregnant, nursing, or under 12 years of age.

Precautions Caution should be used when administering to patients with a history of digestive diseases like gastroduodenal peptic ulcer or gastritis and in patients treated with anticoagulants.

It is known that NSAIDs inhibit the synthesis of prostaglandins which have a supportive role in the maintenance of renal perfusion. In patients with impaired renal blood-flow administration of NSAIDs may precipitate overt renal decompensation, usually reversible with the discontinuation of the product.

Patients at greatest risk of this reaction are dehydrated patients, patients with congestive heart failure, hepatic cirrhosis, nephrotic syndrome or other overt renal diseases, patients taking diuretics or those who underwent major surgeries with subsequent hypovolemia. In these patients diuresis volume and renal function should to be controlled before initiating therapy. During treatment with NSAIDs in some cases transaminase plasma levels or other liver parameters may be increased.

Pregnancy:

Although preclinical toxicological studies performed with Lysine clonixinate did not show teratogenic effects, there is no sufficient experience available with the administration of Dorixina B1, B6, B12 to pregnant women. Therefore it should not be administered during pregnancy.

Nursing:

As the components of this product are excreted in human milk, as a precautionary measure it should not be administered to breast-feeding women.

Pediatric use:

There are no clinical studies available with Lysine clonixinate administered to children under 12 years of age, therefore its use is contraindicated in patients of this age group.

Geriatric use:

Like with other anti-inflammatories, it should be administered with caution to elderly patients, as they may have impairment of their cardiac, hepatic or renal function

• Consult Your Doctor If:

  • You have a history of gastrointestinal conditions, renal impairment, or are taking anticoagulants.

Adverse Reactions

Occasional side effects include nausea, vomiting, gastritis, or somnolence.

Rarely, allergic reactions such as anaphylaxis may occur. These reactions are more frequent during parenteral administration and may include: Cough, difficulty to swallow, pruritus, stiffness of the face, lips and eyelids, sibilance, dyspnea.

Ingestion of the tablets may cause a sensation of abdominal fullness or pyrosis which disappears without the need of treatment discontinuation. Less frequently gastroduodenal ulcer, perforation and occult digestive hemorrhages.

Always follow your doctor’s guidance.

Drug Interactions

Other NSAIDs (including acetylsalicylic acid): Increased risk of peptic ulcer and gastroduodenal hemorrhages and of other adverse effects due to their synergistic action. Oral anticoagulants, ticlopidine, heparin and thrombolytics: Increased risk of hemorrhages. If concomitant administration is unavoidable, close controls of blood coagulation must be performed adjusting the dosage of those medicines which modify coagulation parameters accordingly. Lithium: Usually NSAIDs increase lithium plasma levels. Closely monitor lithium plasma levels when starting, modifying or discontinuing treatment with Dorixina B1, B6, B12. Methotrexate: Concomitant treatment with methotrexate and NSAIDs may increase hematological toxicity of methotrexate. In these cases, close hematological controls should be performed. Diuretics: In dehydrated patients, treatment with NSAIDs increases the potential risk of acute renal failure. In cases of concomitant treatment with Lysine clonixinate and diuretics patients must be properly hydrated and their renal function controlled before initiating treatment. Antihypertensives (for example, beta-adrenergic receptor blocking agents, ACE-inhibitors, vasodilators, diuretics): During concomitant treatment with antihypertensive agents and NSAIDs a decrease in antihypertensive effect has been reported due to the inhibition of vasodilating prostaglandins. Corticosteroids: Concomitant treatment with corticosteroids and NSAIDs increases the risk of gastrointestinal toxicity including peptic ulcer and hemorrhage. Hypoglycemic agents: NSAIDs may increase the hypoglycemic effect of these substances as prostaglandins are directly involved in the regulation of glucose metabolism and probably also due to displacement from protein binding in the case of oral hypoglycemic agents. Probenecid: It may decrease excretion of NSAIDs and increase their plasma levels. Vitamins B1, B6, B12: Following drugs are pyridoxine antagonists and may cause anemia or peripheral neuritis: Chloramphenicol, cycloserine, hydralazine, corticosteroids, azathioprine, chlorambucil, cyclophosphamide, cyclosporine, mercaptopurine, isoniazid, and penicillamine. Estrogens increase pyridoxine requirements. It should not be coadministered with levodopa as 5 mg of pyridoxine revert its anti-parkinsonian effects. Alcohol intake decreases thiamine absorption. Extended release potassium formulations as well as cholestyramine, colchicine, neomycin and amino-salycilates decrease the absorption of vitamin B12. Ascorbic acid may inactivate vitamin B12.

How is Dorixina B1 B6 B12 Supplied?

• Formulation: Film-coated tablets.
• Packaging: Box containing 20 tablets.
• Appearance: Red, cylindrical film-coated tablets.

About the Manufacturer

Dorixina B1 B6 B12 is proudly manufactured by Roemmers S.A.I.C.F., Argentina, and distributed by Droguerie Phenicia in Lebanon.

Back